Overview

Phase I Combination Ixabepilone + Cisplatin

Status:
Completed

Trial end date:
2011-01-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to determine the highest dose of ixabepilone that can be given safely with cisplatin without causing severe or life-threatening side effects and for some patients with non-small cell lung cancer, the effects (good or bad) on your cancer will also be studied

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

R-Pharm

Treatments:

Cisplatin
Epothilones

Criteria

Escalation Phase Subjects: Primary solid tumor not curable by local measures such as
surgery, radiation

Inclusion Criteria:

- Men and women age ≥ 18

Exclusion:

- More than 2 prior chemotherapy containing regimens for metastatic disease

- No prior exposure to cisplatin or ixabepilone

Expansion Phase Subjects: Advanced Non-small cell lung cancer

Inclusion Criteria:

- Men and women age ≥ 18

Exclusion:

- No prior chemotherapy-containing regimen for metastatic disease

- No prior exposure to cisplatin or ixabepilone